
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...



(Alliance News) - The following is a round-up of London-listed company director and manager changes announced this week and not separately reported by...


* Case involved Amarin's cardiovascular drug Vascepa


* Case involved Amarin's cardiovascular drug Vascepa

(Alliance News) - Incanthera PLC on Thursday appointed a new chief executive, who will provide the company with funding to support a new acquisition.

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...

(Alliance News) - Ondine Biomedical Inc on Thursday said higher investment, which is designed to support future growth, impacted margins in 2025.

* Targeted therapies drive rising cancer survival rates, experts say

(Alliance News) - AstraZeneca PLC on Tuesday reported encouraging test results for its breast cancer treatment camizestrant.

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Monday and not separately reported by Alliance ...

* CEPI commits just over $60 million to three vaccine groups

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

(Alliance News) - AstraZeneca PLC on Monday posted positive phase-three trial results for a combination of its drugs Imfinzi and Imjudo to treat a for...

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...

(Alliance News) - AstraZeneca PLC on Friday announced that the CARES phase 3 clinical programme did not meet a primary endpoint, but noted insightful ...

(Alliance News) - CelLBxHealth PLC on Friday disclosed that it has entered a partnership with AstraZeneca PLC.

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately repor...

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Pretax loss narrows to GBP346,577 in the six months ended March 31, fr...

(Alliance News) - GSK PLC on Thursday reported "positive" phase 3 trial data for its hepatitis B treatment, Bepirovirsen, which it said could "redefin...